RDNZ supports Pharmac's proposal to fund risdiplam for SMA
Pharmac is proposing to fund Risdiplam (Evrysdi) for the treatment of symptomatic type 1, 2 and 3a Spinal Muscular Atrophy from 1 May 2023 for those who begin treatment before the age of 18.
Rare Disorders NZ has made a submission to Pharmac on the proposal, expressing support for the funding proposal for Risdiplam which we understand would have the same access criteria as nusinersen (Spinraza).
Rare Disorders NZ supports two funded options for the treatment of symptomatic SMA in New Zealand, especially as Risdiplam would provide an oral treatment option alongside nusinersen.
Read our full submission here.
Consultation closes at 4pm, Friday 24 February 2023.